Core Insights - Pancreatic cancer, known as the "king of cancers," has a high incidence rate globally, with over 120,000 new cases annually in China alone, and over 80% of patients diagnosed at advanced stages, leading to a low five-year survival rate of around 10% [1] - The collaboration between Fosun Health and Ruijin Hospital aims to establish a clinical base for pancreatic disease treatment, addressing the challenges faced by patients in the Greater Bay Area and Southeast Asia [2][4] Group 1: Collaboration Details - The agreement includes a dual-signage approach, with Ruijin Hospital's pancreatic center designated as the "Fosun Health Pancreatic Disease Diagnosis and Treatment Center Clinical Base," while Fosun Health's Foshan Zhencheng Hospital will be recognized as the "Ruijin Hospital Pancreatic Disease Diagnosis and Treatment Center Greater Bay Area Clinical Base" [4] - The partnership will leverage Ruijin Hospital's expertise in pancreatic surgery and multidisciplinary treatment (MDT), while Fosun Health will utilize its international medical platform to provide comprehensive recovery services [4] Group 2: Market Expansion and Global Integration - The collaboration is not limited to domestic resource integration but also represents a significant step for Chinese healthcare to expand internationally, with initiatives already underway in Southeast Asia [5] - The recent "China-Bangladesh Medical Innovation Exchange Summit" showcased the expertise of Ruijin Hospital in multidisciplinary collaboration and postoperative recovery management, enhancing the influence of Chinese medical solutions in the region [5] Group 3: Future Directions - Fosun Health plans to continue its partnership with Ruijin Hospital and other quality medical partners to improve domestic healthcare services and expand international cooperation, aiming to provide safer, more efficient, and accessible treatment solutions for global pancreatic disease patients [7]
复星健康携手瑞金医院共建基地，胰腺癌诊疗迎来新突破